Clinical Responses and Recovery of Hematologic Function in Patients Who Received Treatment With CMA-676
| Clinical Response . | Patient No. . | Age (yr) . | Cytogenetic Abnormality . | Dose Level (mg/m2) . | Peripheral Blasts (per μL) . | Percentage of Marrow Blasts . | Time in Days From Last Dose to: . | Site of Recurrence . | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ANC >1,500/ μL . | Platelet Count >100 × 103/μL . | Relapse . | ||||||||
| CR3-150 | FH-007 | 43 | t(6;11) | 1 | 12 | 50 | 4 | 7 | 132 | Bone; marrow |
| FH-0123-151 | 29 | t(6;9) | 4 | 22,377 | 83 | 20 | 35 | 188 | Testes; central nervous system | |
| FH-0233-151 | 34 | None | 9 | 748 | 60 | 42 | 160 | >623 | None | |
| Elimination of blast cells from peripheral blood and marrow3-152 | FH-013 FH-0193-153 FH-022 FH-024 COH-0153-153 FH-0073-155 | 74 53 65 52 34 43 | None t(8;21) None t(1;7); t(12;17) Trisomy 11; del(15) t(6;11) | 5 6 9 9 9 6 | 1,912 3,560 0 2,445 0 300 | 88 67 8 40 23 95 | Not attained Not attained 18 20 Not attained 8 | Not attained Not attained Not attained Not evaluable3-154 Not attained Not attained | 70 Not applicable 40 14 Not applicable 56 | Marrow Not applicable Marrow; central nervous system Marrow Not applicable Marrow |
| Clinical Response . | Patient No. . | Age (yr) . | Cytogenetic Abnormality . | Dose Level (mg/m2) . | Peripheral Blasts (per μL) . | Percentage of Marrow Blasts . | Time in Days From Last Dose to: . | Site of Recurrence . | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ANC >1,500/ μL . | Platelet Count >100 × 103/μL . | Relapse . | ||||||||
| CR3-150 | FH-007 | 43 | t(6;11) | 1 | 12 | 50 | 4 | 7 | 132 | Bone; marrow |
| FH-0123-151 | 29 | t(6;9) | 4 | 22,377 | 83 | 20 | 35 | 188 | Testes; central nervous system | |
| FH-0233-151 | 34 | None | 9 | 748 | 60 | 42 | 160 | >623 | None | |
| Elimination of blast cells from peripheral blood and marrow3-152 | FH-013 FH-0193-153 FH-022 FH-024 COH-0153-153 FH-0073-155 | 74 53 65 52 34 43 | None t(8;21) None t(1;7); t(12;17) Trisomy 11; del(15) t(6;11) | 5 6 9 9 9 6 | 1,912 3,560 0 2,445 0 300 | 88 67 8 40 23 95 | Not attained Not attained 18 20 Not attained 8 | Not attained Not attained Not attained Not evaluable3-154 Not attained Not attained | 70 Not applicable 40 14 Not applicable 56 | Marrow Not applicable Marrow; central nervous system Marrow Not applicable Marrow |
Patient achieved transfusion independence with ANC >1,500/μL, platelet count >100 × 103/μL, and <5% blasts in the bone marrow aspirate.
Patient received donor lymphocyte infusion after attaining CR (FH-012) or before achieving platelet count >100 × 103/μL (FH-023).
Patient had <5% blasts in the bone marrow aspirate with various degrees of hematopoietic recovery.
Patients died of infection 12 (FH-019) and 50 (COH-015) days after receiving a third dose of CMA-676.
Patient attained CR after receiving CMA-676 at 1 mg/m2and then was retreated with CMA-676 at a dose of 6 mg/m2.
Patient received a bone marrow transplant shortly after leukemia disappeared from the bone marrow and eventually recovered a normal platelet count.